These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 31725440)

  • 21. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Reid PD; Cifu AS; Bass AR
    JAMA; 2021 Feb; 325(5):482-483. PubMed ID: 33528524
    [No Abstract]   [Full Text] [Related]  

  • 23. Neurological sequelae of cancer immunotherapies and targeted therapies.
    Wick W; Hertenstein A; Platten M
    Lancet Oncol; 2016 Dec; 17(12):e529-e541. PubMed ID: 27924751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
    Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
    Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of immunotherapy toxicities in older adults.
    Bhandari S; Gill AS; Perez CA; Jain D
    Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Toxicities Associated with Cancer Immunotherapies.
    Wang DY; Okoye GD; Neilan TG; Johnson DB; Moslehi JJ
    Curr Cardiol Rep; 2017 Mar; 19(3):21. PubMed ID: 28220466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of cancer immunotherapy toxicity.
    Kennedy LB; Salama AKS
    CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurologic Toxicities of Immunotherapy.
    Harrison RA; Majd NK; Tummala S; de Groot JF
    Adv Exp Med Biol; 2021; 1342():417-429. PubMed ID: 34972978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Side effects of cancer immunotherapies : important role for the clinical immunologist].
    Obeid M
    Rev Med Suisse; 2019 Jan; 15(N° 632-633):17-19. PubMed ID: 30629360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
    Davies M
    Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.
    Habre M; Habre SB; Kourie HR
    Immunotherapy; 2016 Dec; 8(12):1437-1446. PubMed ID: 28000535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
    Mistry H; Forbes SG; Fowler N
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):53-59. PubMed ID: 28315558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Supportive therapy and management of side effects in dermato-oncology].
    von Dücker L; Hüning S; Kähler K; Terheyden P; Nashan DRT
    Hautarzt; 2019 Dec; 70(12):975-988. PubMed ID: 31720719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurologic Toxicities of Cancer Immunotherapies: a Review.
    Harrison RA; Tummala S; de Groot J
    Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
    Gutierrez C; Rajendram P; Pastores SM
    Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicities of Immunotherapy for the Practitioner.
    Weber JS; Yang JC; Atkins MB; Disis ML
    J Clin Oncol; 2015 Jun; 33(18):2092-9. PubMed ID: 25918278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurological toxicities associated with immune-checkpoint inhibitors.
    Touat M; Talmasov D; Ricard D; Psimaras D
    Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.
    Vigarios E; Epstein JB; Sibaud V
    Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.